Table 1.
Characteristics of the prospective and retrospective cohorts
|
Prospective cohort |
Retrospective cohort |
||||
|---|---|---|---|---|---|
| First booster (n=1785) | Second booster (n=699) | First and second booster (n=446) | First booster (n=94 169) | First and second booster* (n=17 814) | |
| Sex | |||||
| Male | 866 (48·5%) | 348 (48·8%) | 215 (48·2%) | 45 208 (48·0%) | 8879 (49·8%) |
| Female | 919 (51·5%) | 350 (50·2%) | 231 (51·8%) | 48 961 (52·0%) | 8935 (50·2%) |
| Unspecified | 0 (0%) | 1 (<1%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Age group, years | |||||
| Median (IQR) | 52 (34–61) | 62 (53–68) | 64 (57–70) | 47 (31–61) | 69 (62–76) |
| 0–29 years | 275 (15·4%) | 26 (3·7%) | 11 (2·5%) | 21 711 (23·1%) | 285 (1·6%) |
| 30–39 years | 350 (19·6%) | 55 (7·9%) | 23 (5·2%) | 14 445 (15·3%) | 489 (2·8%) |
| 40–49 years | 201 (11·3%) | 61 (8·7%) | 22 (4·9%) | 15 514 (16·5%) | 799 (4·5%) |
| 50–59 years | 429 (24·0%) | 130 (18·6%) | 86 (19·3%) | 16 650 (17·7%) | 1850 (10·4%) |
| 60–69 years | 362 (20·3%) | 277 (39·6%) | 185 (41·5%) | 12 596 (13·4%) | 5770 (32·4%) |
| 70 years | 168 (9·4%) | 150 (21·5%) | 119 (26·7%) | 13 253 (14·1%) | 8621 (48·4%) |
| BMI† | |||||
| Median (IQR) | 26·04 (23·33–29·23) | 26·80 (24·42–29·98) | 26·96 (24·61–30·07) | 25·35 (22·20–29·06) | 27·27 (24·38–30·66) |
| <30·0 | 1381 (77·4%) | 510 (73·0%) | 318 (71·3%) | 71 347 (75·8%) | 12 476 (70·0%) |
| ≥30·0 | 363 (20·3%) | 170 (24·3%) | 110 (24·7%) | 18 650 (19·8%) | 5098 (28·6%) |
| Unspecified | 41 (2·3%) | 19 (2·7%) | 18 (4·0%) | 4172 (4·4%) | 240 (1·4%) |
| Comorbidities‡ | |||||
| Yes | 397 (22·2%) | 260 (37·2%) | 186 (41·7%) | 24 585 (26·1%) | 10 781 (60·5%) |
| No | 1342 (75·2%) | 412 (58·9%) | 238 (53·4%) | 69 584 (73·9%) | 7033 (39·5%) |
| Unspecified | 46 (2·6%) | 27 (3·9%) | 22 (4·9%) | 0 (0%) | 0 (0%) |
| Population sector | |||||
| General Jewish | 1570 (88·0%) | 637 (91·1%) | 411 (92·2%) | 82 954 (88·1%) | 16 613 (93·3%) |
| Ultra-Orthodox Jewish | 37 (2·07%) | 8 (1·15%) | 6 (1·35%) | 3797 (4·03%) | 412 (2·31%) |
| Religious (non-ultra-Orthodox) Jewish | 71 (4·0%) | 27 (3·9%) | 17 (3·8%) | 3355 (3·6%) | 488 (2·7%) |
| Arab | 18 (1·0%) | 1 (<1%) | 0 (0%) | 4046 (4·3%) | 300 (1·7%) |
| Unspecified | 89 (5·0%) | 26 (3·7%) | 12 (2·7%) | 17 (<1%) | 1 (<1%) |
| Time between first and second booster | |||||
| Median, days (IQR) | NA | 158 (153–174) | 157 (153–172) | NA | 157 (153–169) |
NA=not applicable.
*
All participants who received a second dose were documented in the medical records with the first booster as well.
†
The BMI is the weight in kilograms divided by the square of the height in metres.
‡
Comorbidities were at least one of the following: hypertension, diabetes, heart disease, chronic lung disease, immune suppression, cancer, or renal failure.